JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, arising from
immature lymphocytes that show uncontrolled proliferation and arrested differentiation …
immature lymphocytes that show uncontrolled proliferation and arrested differentiation …
Novel treatment strategies for chronic myeloid leukemia
Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia
(CML) from a lethal blood cancer into a chronic condition. As patients with access to …
(CML) from a lethal blood cancer into a chronic condition. As patients with access to …
Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire
Bcr‐Abl, a nonreceptor tyrosine kinase, is associated with leukemias, especially chronic
myeloid leukemia (CML). Deletion of Abl's N‐terminal region, to which myristoyl is linked …
myeloid leukemia (CML). Deletion of Abl's N‐terminal region, to which myristoyl is linked …
Application of thiol–yne/thiol–ene reactions for peptide and protein macrocyclizations
The application of thiol–yne/thiol–ene reactions to synthesize mono‐and bicyclic‐stapled
peptides and proteins is reported. First, a thiol–ene‐based peptide‐stapling method in …
peptides and proteins is reported. First, a thiol–ene‐based peptide‐stapling method in …
Structural insights into the tyrosine phosphorylation–mediated inhibition of SH3 domain–ligand interactions
Src homology 3 (SH3) domains bind proline-rich linear motifs in eukaryotes. By mediating
inter-and intramolecular interactions, they regulate the functions of many proteins involved in …
inter-and intramolecular interactions, they regulate the functions of many proteins involved in …
Emerging role of genomic rearrangements in breast cancer: applying knowledge from other cancers
BS Paratala, SC Dolfi, H Khiabanian… - Biomarkers in …, 2016 - journals.sagepub.com
Significant advances in our knowledge of cancer genomes are rapidly changing the way we
think about tumor biology and the heterogeneity of cancer. Recent successes in genomically …
think about tumor biology and the heterogeneity of cancer. Recent successes in genomically …
Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs
DM Martins, PO Fernandes, LA Vieira… - …, 2024 - Wiley Online Library
The human protein Abelson kinase (Abl), a tyrosine kinase, plays a pivotal role in
develo** chronic myeloid leukemia (CML). Abl's involvement in various signaling …
develo** chronic myeloid leukemia (CML). Abl's involvement in various signaling …
Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide
BJ Bruno, CS Lim - Molecular Pharmaceutics, 2015 - ACS Publications
The oncoprotein Bcr-Abl is the cause of chronic myeloid leukemia (CML). 1 Current
therapies target the tyrosine kinase domain of Bcr-Abl, but resistance to these drugs is …
therapies target the tyrosine kinase domain of Bcr-Abl, but resistance to these drugs is …
Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells
Y Peng, Z Huang, F Zhou, T Wang, K Mou… - Cell Communication and …, 2021 - Springer
Abstract Background The fusion oncoprotein Bcr-Abl is mostly located in the cytoplasm,
which causes chronic myeloid leukemia (CML). After moving into the nucleus, the fusion …
which causes chronic myeloid leukemia (CML). After moving into the nucleus, the fusion …
Computational modeling of stapled peptides toward a treatment strategy for CML and broader implications in the design of lengthy peptide therapeutics
The oncogenic gene product Bcr-Abl is the principal cause of chronic myeloid leukemia, and
although several therapies exist to curb the aberrant kinase activity of Bcr-Abl through …
although several therapies exist to curb the aberrant kinase activity of Bcr-Abl through …